Patrick W. Vincent

Zanzibar University — TZ

Biochemistry, Genetics and Molecular Biology · Life Sciences

29h-index7.7kcitations130works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(33), HER2/EGFR in Cancer Research(21), Lung Cancer Treatments and Mutations(15), Quinazolinone synthesis and applications(13), Synthesis and biological activity(10)

Publications129 total

Accelerated MRI Reconstruction: Evaluating Physics-Informed Sampling Against Learning-Based Methods
2025
Optimization of mTOR Inhibitors Using Property-Based Drug Design and Free–Wilson Analysis for Improved In Vivo Efficacy
ACS Medicinal Chemistry Letters·2023· 1 citedOpen Access
Effect of foot stato-dynamic disorders on hemodynamics of the lower limb using strain-gauge plethysmography
Journal of Vascular Surgery Venous and Lymphatic Disorders·2023· 2 citedOpen Access
Effect of dysmorphic plantar arch on venous hemodynamics of the lower limb
Phlebology The Journal of Venous Disease·2023· 2 citedOpen Access
Suppl Figure 6 from Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants
2023Open Access
Data from Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants
2023Open Access
Suppl Figure 2 from Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants
2023Open Access
Suppl Figure 4 from Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants
2023Open Access
Suppl Table 1 from Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants
2023Open Access
Supplementary Figure Legends from Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants
2023Open Access
Suppl Table 1 from Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants
2023Open Access
Suppl Figure 3 from Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants
2023Open Access
Suppl Table 2 from Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants
2023Open Access
Suppl Figure 4 from Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants
2023Open Access
Suppl Table 3 from Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants
2023Open Access
Suppl Figure 2 from Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants
2023Open Access
Suppl Figure 3 from Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants
2023Open Access
Suppl Figure 5 from Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants
2023Open Access
Suppl Figure 1 from Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants
2023Open Access
Supplementary Figure Legends from Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants
2023Open Access
page 1 of 7Next →

Frequent Co-authors

William L. Elliott(12), H. D. Hollis Showalter(11), James M. Nelson(9), David W. Fry(9), William A. Denny(8), Patrick Blondin(6), Lawrence C. Smith(5), Billy Roberts(5), Patrick Moreau(5), Claude Cassagne(5), Alan J. Kraker(5), Jeff B. Smaill(4), Gordon W. Rewcastle(4), R. Thomas Winters(4), Hairong Zhou(4), James M. Hamby(4), Wayne D. Klohs(4), Denise L. Driscoll(4), Gina H. Lu(4), Bill J. Roberts(4)